Literature DB >> 14604449

Psychotic symptoms in methamphetamine psychotic in-patients.

Manit Srisurapanont1, Robert Ali, John Marsden, Agueda Sunga, Kiyoshi Wada, Maristela Monteiro.   

Abstract

The present study was aimed at exploring the prevalence and factor structure of methamphetamine (MA) psychotic symptoms. The data were obtained from a cross-country evaluation of substance use, health, and treatment in MA psychotic in-patients. The prevalence rates of lifetime and current psychotic symptoms were determined by using Mini-International Neurospychiatric Interview-Plus, Module M. The Manchester scale was used to assess the severity of psychotic symptoms during the week prior to assessment. All eight items of the Manchester scale were subjected to principal-component analysis, eigenvalue one test, and varimax rotation. The data of 168 patients (127 male and 41 female) included in the analyses were obtained from Australia, Japan, the Philippines and Thailand. Persecutory delusion was the most common lifetime psychotic symptom found in 130 participants (77.4%), followed by auditory hallucinations, strange or unusual beliefs, and thought reading. Auditory hallucinations were the most common current symptom found in 75 participants (44.6%), followed by strange or unusual beliefs and visual hallucinations. Current negative symptoms were also found in 36 patients (21.4%). Apart from a factor of anxiety and depression, the results yielded a two-factor model of MA psychotic symptoms, which were negative and positive/disorganized syndromes. The negative syndrome comprised poverty of speech, psychomotor retardation, and flattened/incongruous affects. The positive syndrome consisted of delusions, hallucinations, and incoherent speech. Both positive/disorganized and negative syndromes should be taken into account in assessing MA psychotic symptoms. The clinical findings do not support the shortcomings of amphetamine-induced psychosis in modelling the negative symptoms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604449     DOI: 10.1017/S1461145703003675

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  40 in total

1.  The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice.

Authors:  Sarah E Snider; Sarah A Vunck; Edwin J C G van den Oord; Daniel E Adkins; Joseph L McClay; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2012-01-28       Impact factor: 4.432

Review 2.  Neurocognitive effects of methamphetamine: a critical review and meta-analysis.

Authors:  J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

Review 3.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

4.  Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users.

Authors:  Paul S Frankel; Mario E Alburges; Lloyd Bush; Glen R Hanson; Stephen J Kish
Journal:  Neuropharmacology       Date:  2008-04-29       Impact factor: 5.250

Review 5.  Neurologic manifestations of chronic methamphetamine abuse.

Authors:  Daniel E Rusyniak
Journal:  Neurol Clin       Date:  2011-06-24       Impact factor: 3.806

Review 6.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

7.  Profiles of psychiatric symptoms among amphetamine type stimulant and ketamine using inpatients in Wuhan, China.

Authors:  Yao Zhang; Zaifeng Xu; Sheng Zhang; Alethea Desrosiers; Richard S Schottenfeld; Marek C Chawarski
Journal:  J Psychiatr Res       Date:  2014-02-24       Impact factor: 4.791

8.  Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C→T in a Thai treatment cohort.

Authors:  Rasmon Kalayasiri; Viroj Verachai; Joel Gelernter; Apiwat Mutirangura; Robert T Malison
Journal:  Addiction       Date:  2014-03-17       Impact factor: 6.526

9.  Glial cell modulators attenuate methamphetamine self-administration in the rat.

Authors:  Sarah E Snider; Elizabeth S Hendrick; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2013-01-31       Impact factor: 4.432

Review 10.  Neurologic manifestations of chronic methamphetamine abuse.

Authors:  Daniel E Rusyniak
Journal:  Psychiatr Clin North Am       Date:  2013-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.